ABS-201 IV Single Dose + Placebo IV + ABS-201 SC Multiple Doses + Placebo SC Injection

Phase 1/2Recruiting

1 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Androgenetic Alopecia (AGA)

Conditions

Androgenetic Alopecia (AGA), Healthy Volunteers - Male and Female

Trial Timeline

Dec 3, 2025 → Jul 1, 2028

NCT ID

NCT07317544

About ABS-201 IV Single Dose + Placebo IV + ABS-201 SC Multiple Doses + Placebo SC Injection

ABS-201 IV Single Dose + Placebo IV + ABS-201 SC Multiple Doses + Placebo SC Injection is a phase 1/2 stage product being developed by AbSci for Androgenetic Alopecia (AGA). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07317544. Target conditions include Androgenetic Alopecia (AGA), Healthy Volunteers - Male and Female.

What happened to similar drugs?

0 of 7 similar drugs in Androgenetic Alopecia (AGA) were approved

Approved (0) Terminated (0) Active (7)

🔄minoxidilJohnson & JohnsonPhase 3

🔄5% Minoxidil Topical Foam + Vehicle Topical FoamJohnson & JohnsonPhase 3

🔄Clascoterone 5% solution + Vehicle solutionICON plc.Phase 3

🔄VDPHL01 QD + Placebo + VDPHL01 BID + PlaceboVeradermicsPhase 3

🔄VDPHL01 + PlaceboVeradermicsPhase 3

🔄MK0906, finasteride / Duration of Treatment : 48 Weeks + Comparator : placebo (unspecified) / Duration of Treatment : 48 WeeksOrganonPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07317544	Phase 1/2	Recruiting	Dec 3, 2025	Jul 1, 2028	Androgenetic Alopecia (AGA)

Competing Products

12 competing products in Androgenetic Alopecia (AGA)

See all competitors

Product	Company	Stage	Hype Score
minoxidil	Johnson & Johnson	Phase 3	40
Minoxidil + vehicle of 5% Minoxidil topical foam	Johnson & Johnson	Phase 2	35
5% Minoxidil Topical Foam + Vehicle Topical Foam	Johnson & Johnson	Phase 3	40
Cyproterone Acetate (Androcur, BAY94-8367)	Bayer	Pre-clinical	23
Clascoterone 5% solution + Vehicle solution	ICON plc.	Phase 3	37
Clascoterone 5% solution + Vehicle solution	ICON plc.	Phase 3	41
VDPHL01	Veradermics	Phase 2	33
VDPHL01 QD + Placebo + VDPHL01 BID + Placebo	Veradermics	Phase 3	41
VDPHL01 + Placebo	Veradermics	Phase 2/3	36
VDPHL01 + Placebo	Veradermics	Phase 3	38
MK0906, finasteride / Duration of Treatment : 48 Weeks + Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks	Organon	Phase 3	34
ATI-50002	Aclaris Therapeutics	Phase 2	25